NASDAQ:YMTX - Yumanity Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $37.00
  • Forecasted Upside: 234.84 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$11.05
▼ -0.99 (-8.22%)

This chart shows the closing price for YMTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Yumanity Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for YMTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for YMTX

Analyst Price Target is $37.00
▲ +234.84% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Yumanity Therapeutics in the last 3 months. The average price target is $37.00, with a high forecast of $39.00 and a low forecast of $35.00. The average price target represents a 234.84% upside from the last price of $11.05.

This chart shows the closing price for YMTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Yumanity Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/4/2021HC WainwrightInitiated CoverageBuy$39.00High
4/1/2021Jefferies Financial GroupInitiated CoverageBuy$35.00N/A
12/23/2020Piper SandlerReiterated RatingOverweightN/A
(Data available from 9/19/2016 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/20/2021
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/19/2021

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Yumanity Therapeutics logo
Yumanity Therapeutics, Inc. is a clinical stage biopharmaceuticals company. It is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform. Its platform is based on technology, which enables the rapid screening for novel disease targets and disease modifying drugs that can overcome toxicity in disease-causing gene networks, which usually results from an aberrant accumulation of misfolded proteins in the brain. The company was founded by Susan Lindquist and Tony Coles in December 2014 and is headquartered in Boston, MA.
Read More

Today's Range

Now: $11.05
Low: $10.81
High: $12.40

50 Day Range

MA: $10.03
Low: $8.30
High: $12.04

52 Week Range

Now: $11.05
Low: $8.21
High: $27.00

Volume

602,560 shs

Average Volume

97,939 shs

Market Capitalization

$113.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72

Frequently Asked Questions

What sell-side analysts currently cover shares of Yumanity Therapeutics?

The following equities research analysts have issued research reports on Yumanity Therapeutics in the last twelve months: HC Wainwright, Jefferies Financial Group Inc., Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for YMTX.

What is the current price target for Yumanity Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Yumanity Therapeutics in the last year. Their average twelve-month price target is $37.00, suggesting a possible upside of 234.8%. HC Wainwright has the highest price target set, predicting YMTX will reach $39.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $35.00 for Yumanity Therapeutics in the next year.
View the latest price targets for YMTX.

What is the current consensus analyst rating for Yumanity Therapeutics?

Yumanity Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe YMTX will outperform the market and that investors should add to their positions of Yumanity Therapeutics.
View the latest ratings for YMTX.

What other companies compete with Yumanity Therapeutics?

How do I contact Yumanity Therapeutics' investor relations team?

Yumanity Therapeutics' physical mailing address is 40 GUEST STREET SUITE 4410, BOSTON MA, 02135. The company's listed phone number is (617) 409-5300 and its investor relations email address is [email protected] The official website for Yumanity Therapeutics is www.yumanity.com.